logo
Share SHARE
FONT-SIZE Plus   Neg

Biogen: US And EU Regulators Accept Plegridy Marketing Applications For Review

Biogen Idec (BIIB) announced Friday that U.S. and EU regulatory authorities have accepted the marketing applications for the review of Plegridy (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis or MS.

The U.S. Food and Drug Administration or FDA has accepted Biogen Idec's Biologics License Application or BLA for marketing approval of Plegridy in the United States and granted the company a standard review timeline. The Marketing Authorisation Application or MAA of Plegridy for review in the European Union was also validated by the European Medicines Agency.

The regulatory applications included positive one-year results from the two-year global Phase 3 Advance study. The data demonstrated that PLEGRIDY met all primary and secondary endpoints by significantly reducing disease activity including relapses, disability progression and brain lesions compared to placebo, and showed favorable safety and tolerability profiles at one year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
German steel giant ThyssenKrupp AG reported a loss in its first quarter, compared to last year's profit as sales and orders were hurt by sharp deterioration in materials businesses. The company said its overall performance in the first quarter was within its full-year forecast corridor. Looking ahead, the company continues to expect higher net income and flat sales for fiscal 2016. German lender Commerzbank AG reported a profit in its fourth quarter, compared to last year's loss, particularly benefited by lower loan loss provisions. Chairman Martin Blessing noted that its for the first time in five years that the bank attained a net profit of more than 1 billion euros. Looking ahead, for fiscal 2016, the bank expects a slight increase in net profit from the prior year. Activision Blizzard Inc. (ATVI) on Thursday reported a drop in profit for the fourth quarter, as revenues declined reflecting weak demand for Skylanders SuperChargers and Guitar Hero Live. The video game publisher's profit and revenues fell short of Wall Street estimates. Moving ahead, the company detailed...
comments powered by Disqus
RELATED NEWS
Trade BIIB now with 
Follow RTT